EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Repeated OGTT Versus Continuous Glucose Monitoring for Predicting Development of Stage 3 Type 1 Diabetes: A Longitudinal Analysis

Aster K Desouter iD, Bart Keymeulen iD, Ursule Van de Velde, Annelien Van Dalem iD, Bruno Lapauw iD, Christophe De Block iD, Pieter Gillard iD, Nicole Seret, Eric V Balti iD, Elena R Van Vooren, Willem Staels iD, Sara Van Aken iD und 5 weitere

Diabetes Care · 01.04.2025 · 48 (4) · 528-536

DOI: 10.2337/dc24-2376 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Diabetes Care, online erschienen am 04.02.2025. Verfasst von Aster K Desouter und 16 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Research Center, Vrije Universiteit Brussel (VUB), Brussels, Belgium. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Blood Glucose, Blood Glucose Self-Monitoring. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fonds Wetenschappelijk Onderzoek, Departement Economie, Wetenschap en Innovatie, Wetenschappelijk Fonds Willy Gepts, Universitair Ziekenhuis Brussel.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Evidence for using continuous glucose monitoring (CGM) as an alternative to oral glucose tolerance tests (OGTTs) in presymptomatic type 1 diabetes is primarily cross-sectional. We used longitudinal data to compare the diagnostic performance of repeated CGM, HbA1c, and OGTT metrics to predict progression to stage 3 type 1 diabetes. RESEARCH DESIGN AND METHODS Thirty-four multiple autoantibody-positive first-degree relatives (FDRs) (BMI SD score [SDS] <2) were followed in a multicenter study with semiannual 5-day CGM recordings, HbA1c, and OGTT for a median of 3.5 (interquartile range [IQR] 2.0–7.5) years. Longitudinal patterns were compared based on progression status. Prediction of rapid (<3 years) and overall progression to stage 3 was assessed using receiver operating characteristic (ROC) areas under the curve (AUCs), Kaplan-Meier method, baseline Cox proportional hazards models (concordance), and extended Cox proportional hazards models with time-varying covariates in multiple record data (n = 197 OGTTs and concomitant CGM recordings), adjusted for intraindividual correlations (corrected Akaike information criterion [AICc]). RESULTS After a median of 40 (IQR 20–91) months, 17 of 34 FDRs (baseline median age 16.6 years) developed stage 3 type 1 diabetes. CGM metrics increased close to onset, paralleling changes in OGTT, both with substantial intra- and interindividual variability. Cross-sectionally, the best OGTT and CGM metrics similarly predicted rapid (ROC AUC = 0.86–0.92) and overall progression (concordance = 0.73–0.78). In longitudinal models, OGTT-derived AUC glucose (AICc = 71) outperformed the best CGM metric (AICc = 75) and HbA1c (AICc = 80) (all P < 0.001). HbA1c complemented repeated CGM metrics (AICc = 68), though OGTT-based multivariable models remained superior (AICc = 59). CONCLUSIONS In longitudinal models, repeated CGM and HbA1c were nearly as effective as OGTT in predicting stage 3 type 1 diabetes and may be more convenient for long-term clinical monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 1Blood GlucoseBlood Glucose Self-MonitoringHumansGlucose Tolerance TestMaleFemaleLongitudinal StudiesAdolescentChildGlycated HemoglobinAdultYoung AdultDisease ProgressionContinuous Glucose Monitoring

Substanzen

Blood GlucoseGlycated Hemoglobin

Autor:innen und Institutionen

  • Diabetes Research Center, Vrije Universiteit Brussel (VUB), Brussels, Belgium.
  • Diabetes Clinic, Department of Diabetology and Endocrinology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
  • Clinical Chemistry and Radioimmunology Laboratory, Department of Clinical Biology, Universitair Ziekenhuis Brussel, Brussels, Belgium.
  • Department of Endocrinology, Ghent University Hospital, Ghent, Belgium.
  • Diabetes Unit, Department of Endocrinology, Diabetology and Metabolism, University of Antwerp-Antwerp University Hospital, Antwerp, Belgium.
  • Diabetes Center, Department of Endocrinology, University Hospital Leuven-KU Leuven, Leuven, Belgium.

ORCID-Profile: Aster K Desouter, Bart Keymeulen, Annelien Van Dalem, Bruno Lapauw, Christophe De Block, Pieter Gillard, Eric V Balti, Willem Staels, Sara Van Aken, Marieke den Brinker, Joke Marlier, Hasan Kahya, Frans K Gorus

Förderung

  • Fonds Wetenschappelijk Onderzoek
  • Departement Economie, Wetenschap en Innovatie
  • Wetenschappelijk Fonds Willy Gepts, Universitair Ziekenhuis Brussel
  • Center for Medical Innovation Flanders
  • Medtronic Europe
  • Bayer

Zitieren

APA

Desouter, A. K., Keymeulen, B., Van de Velde, U., Van Dalem, A., Lapauw, B., De Block, C., Gillard, P., Seret, N., Balti, E. V., Van Vooren, E. R., Staels, W., Van Aken, S., den Brinker, M., Depoorter, S., Marlier, J., Kahya, H., & Gorus, F. K. (2025). Repeated OGTT Versus Continuous Glucose Monitoring for Predicting Development of Stage 3 Type 1 Diabetes: A Longitudinal Analysis. Diabetes Care, 48(4), 528-536. https://doi.org/10.2337/dc24-2376

Vancouver

Desouter AK, Keymeulen B, Van de Velde U, Van Dalem A, Lapauw B, De Block C, et al. Repeated OGTT Versus Continuous Glucose Monitoring for Predicting Development of Stage 3 Type 1 Diabetes: A Longitudinal Analysis. Diabetes Care. 2025;48(4):528-536. doi:10.2337/dc24-2376

BibTeX
@article{Desouter2025,
  author = {Desouter, Aster K and Keymeulen, Bart and Van de Velde, Ursule and Van Dalem, Annelien and Lapauw, Bruno and De Block, Christophe and Gillard, Pieter and Seret, Nicole and Balti, Eric V and Van Vooren, Elena R and Staels, Willem and Van Aken, Sara and den Brinker, Marieke and Depoorter, Sylvia and Marlier, Joke and Kahya, Hasan and Gorus, Frans K},
  title = {Repeated OGTT Versus Continuous Glucose Monitoring for Predicting Development of Stage 3 Type 1 Diabetes: A Longitudinal Analysis},
  journal = {Diabetes Care},
  year = {2025},
  volume = {48},
  number = {4},
  pages = {528--536},
  doi = {10.2337/dc24-2376}
}
Kostenlos starten →